Overactive Bladder and the β3-Adrenoceptor Agonists: Current Strategy and Future Prospects.

Area of Science:

• Pharmacology
• Urology

Background:

• Overactive bladder (OAB) is a prevalent syndrome characterized by urgency, frequency, and nocturia.
• OAB significantly impacts patients' physical functioning and psychological well-being.
• Current OAB treatments include lifestyle changes and antimuscarinic agents.

Purpose of the Study:

• To review the mode of action, efficacy, and tolerability of mirabegron.
• To discuss the role of mirabegron and other β3-adrenoceptor agonists in OAB treatment algorithms.
• To consider the adverse events associated with antimuscarinics.

Main Methods:

• Literature review focusing on mirabegron.
• Analysis of clinical trial data on mirabegron's efficacy and safety.
• Comparison of mirabegron with established antimuscarinic treatments.

Main Results:

• Mirabegron represents a new class of drugs for OAB treatment.
• The review evaluates mirabegron's mechanism, effectiveness, and side effect profile.
• Adverse events of antimuscarinics are considered in the context of mirabegron's use.

Conclusions:

• Mirabegron offers a valuable therapeutic option for OAB.
• β3-adrenoceptor agonists are emerging as important agents in OAB management.
• Future prospects include tailored drug therapies and combination regimens for OAB.